

SUPPLEMENTARY DATA: ONLINE RESOURCE 2

Development and preliminary evaluation of an assessment of the age-appropriateness/age-inappropriateness of formulations used in children

International Journal of Clinical Pharmacy (IJCP)

Jennifer C. Duncan^{1*}, Louise E. Bracken¹, Anthony J. Nunn^{1,2}, Matthew Peak^{1,2}, Mark A. Turner^{1,2,3}

*Corresponding Author: Jennifer.Duncan@alderhey.nhs.uk

1 Paediatric Medicines Research Unit, Institute in the Park, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom 2 Department of Women's & Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom 3 Liverpool Women's NHS Foundation Trust, Liverpool, United Kingdom.

Figure S3. % of AaFs v AiFs identified across age groups at AH




Figure S4. % of AaFs v AiFs identified across age groups at LWH




Table S5. Final assessment outcome results across the age groups at AH (n = 1,758 MAEs)

AaF Assessment Code	Age group							Total (N)
	Term neonate (as % of n)	Infant (as % of n)	Toddler (as % of n)	Young child (as % of n)	Older child (as % of n)	Teenager (as % of n)	Adolescent (as % of n)	
Number of Patients	37	102	33	60	49	35	18	334
AaF	11 (10.4)	141 (29.7)	61 (30.2)	88 (24.4)	95 (37.0)	103 (50.0)	98 (64.1)	597 (34.0)
AiF (OL)	14 (13.2)	47 (9.9)	21 (10.4)	39 (10.8)	20 (7.8)	9 (4.4)	1 (0.7)	151 (8.6)
AiF (UL)		12 (2.5)	5 (2.5)	23 (6.4)	8 (3.1)	2 (1.0)		50 (2.8)
M (OL)	50 (47.2)	179 (37.8)	90 (44.6)	143 (39.7)	94 (36.6)	65 (31.6)	28 (18.3)	649 (36.9)
M (UL)	30 (28.3)	85 (17.9)	22 (10.9)	64 (17.8)	30 (11.7)	24 (11.7)	21 (13.7)	276 (15.7)
MD		6 (1.3)	3 (1.5)	1 (0.3)	5 (1.9)	3 (1.5)	3 (2.0)	21 (1.2)
U	1 (0.9)	4 (0.8)		2 (0.6)	5 (1.9)		2 (1.3)	14 (0.8)
Total MAEs (n)	106	474	202	360	257	206	153	1758
Total AiF (as % of N)	14 (7.0)	59 (29.4)	26 (12.9)	62 (30.8)	28 (13.9)	11 (5.5)	1 (0.5)	201
Total AaF (as % of N)	11 (1.8)	141 (23.6)	61 (10.2)	88 (14.7)	95 (15.9)	103 (17.3)	98 (16.4)	597

Table S6. Final assessment outcome results across the age groups at LWH (n = 441 MAEs)

AaF Assessment Code	Age group					Total (N)
	Extremely preterm neonate (as % of n)	Very preterm neonate (as % of n)	Moderate to late preterm neonate (as % of n)	Term neonate (as % of n)	Infant (as % of n)	
Number of Patients	8	31	38	14	2	93
AaF	15 (34.9)	39 (24.4)	19 (12.6)	16 (24.2)	1 (4.8)	90 (20.4)
AiF (OL)	7 (16.3)	23 (14.4)	12 (7.9)	9 (13.6)	3 (14.3)	54 (12.2)
AiF (UL)			4 (2.6)			4 (0.9)
M (OL)	16(37.2)	89 (55.6)	97 (64.2)	30 (45.5)	10 (47.6)	242 (54.9)
M (UL)	5 (11.6)	7 (4.4)	19 (12.6)	11 (16.7)	7 (33.3)	49 (11.1)
MD						0 (0.0)
U		2 (1.3)				2 (0.5)
Total MAEs (n)	43	160	151	66	21	441
Total AiF (as % of N)	7 (12.1)	23 (39.7)	16 (27.6)	9 (15.5)	3 (5.2)	58
Total AaF (as % of N)	15 (16.7)	39 (43.3)	19 (21.1)	16 (17.8)	1 (1.1)	90